Oncology Pulse Survey Results

The phase 3 CAPItello-290 trial of capivasertib plus paclitaxel did not meet its primary end point of improved overall survival in the frontline setting of metastatic triple-negative breast cancer.

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

The magnitude of benefit with durvalumab was particularly consistent within prophylactic cranial irradiation and radiation subgroups in the ADRIATIC trial.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Genomic subtype was associated with relapse, occurring in nearly 50% of PAX5-altered pediatric acute lymphoblastic leukemia cases.

Patients with certain solid tumors may be eligible for subcutaneous atezolizumab and hyaluronidase-tqjs, which is now approved by the FDA.